Terms ending in 2039
Every in-force patent on Eyepoint, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,329,859 | Bioerodible Drug Delivery Devices In force · Medium confidence | Eyepoint Pharmaceuticals, Inc. | In force | Medium confidence | |
| US 12,514,823 | Bioerodible Drug Delivery Devices In force · Medium confidence | Eyepoint Pharmaceuticals, Inc. | In force | Medium confidence | |
| US 10,894,824 | Multispecific Antibodies That Target Hptp-B (VE-PTP) and VEGF In force · High confidence | Eyepoint, Inc. | In force | High confidence | |
| US 11,873,334 | Method of Treating Ocular Conditions by Administering an Antibody That Activates TIE2 and Binds VEGF In force · High confidence | Eyepoint, Inc. | In force | High confidence | |
| US 12,398,204 | Method of Treating an Ocular Condition by Administering Multispecific Antibodies That Activates TIE2 and Binds a Receptor Tyrosine Kinase Agonist In force · High confidence | Eyepoint, Inc. | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.